Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by 9c

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

February 24, 2021 4:02 PM EST

- LUPKYNISTM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death -

- Cash, cash equivalents, and investments of $423 million at December 31, 2020

- Conference call to be hosted today at 4:30 p.m. ET -

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today issued its financial results for the fourth quarter and year ended... More